July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Prospective Randomized Controlled Trial of Combination Ranibizumab and Indomethacin for Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • Andrea Russo
    Univ degli Studi di Brescia - Italy, Brescia, Italy
  • Elena Gambicorti
    Univ degli Studi di Brescia - Italy, Brescia, Italy
  • Francesco Morescalchi
    Univ degli Studi di Brescia - Italy, Brescia, Italy
  • Francesco Semeraro
    Univ degli Studi di Brescia - Italy, Brescia, Italy
  • Footnotes
    Commercial Relationships   Andrea Russo, None; Elena Gambicorti, None; Francesco Morescalchi, None; Francesco Semeraro, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 803. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andrea Russo, Elena Gambicorti, Francesco Morescalchi, Francesco Semeraro; Prospective Randomized Controlled Trial of Combination Ranibizumab and Indomethacin for Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2018;59(9):803.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate whether indomethacin eyedrops and ranibizumab intravitreal (IVR) injections would provide additional benefit over ranibizumab alone in the treatment of choroidal neovascularization (CNV).

Methods : This was a randomized, prospective pilot study of eyes with new-onset CNV. Fifty-eight patients were randomized 1:1 into a ranibizumab monotherapy (RM) group and a ranibizumab plus indomethacin (RI) group. All patients received monthly 0.5 mg IVR injections for 3 months, followed by monthly injections administered as needed. RI group patients also self-administered one drop of 0.5% indomethacin three times a day for 12 months. All patients were followed up for 12 months.

Results : At 12 months, both groups showed significant improvement in BCVA and CRT. The mean BCVA change from baseline to 12 months was -0.12 ± 0.04 LogMAR and -0.20 ± 0.04 LogMAR in the RM and RI groups, respectively. At 12 months, the mean CRT (±SE) was -316 ± 41.2 µm and -287 ± 31.5 µm in the RM and RI groups, respectively. The mean required number of IVR injections was 7.38 ± 0.78 and 6.34 ± 0.67 in the RM and RI groups, respectively (P < 0.001).

Conclusions : Compared to IVR monotherapy, combination therapy with indomethacin eyedrops and IVR provides superior anatomical and visual outcomes in patients with naïve CNV lesions. Moreover, topical indomethacin might reduce the frequency of IVR injections, which is very beneficial considering the chronic and expensive nature of IVR therapy.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×